Dipeptidyl peptidase 8 and 9 - Guilty by association?

Frontiers in Bioscience

Volumn 14, Issue 10, 2009, Pages 3619-3633

  Pitman, Melissa R ^a   Sulda, Melanie L ^a,b   Kuss, Bryone ^b   Abbott, Catherine A ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Dipeptidyl peptidase; Inhibitor; Review; Substrates; Talabostat; Val boro pro

Indexed keywords

DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE 8, RAT; DIPEPTIDYL PEPTIDASE 9, RAT; PROTEINASE INHIBITOR;

ANIMAL; DRUG ANTAGONISM; ENZYME SPECIFICITY; GENETICS; HUMAN; METABOLISM; PROTEIN BINDING; PROTEIN PROCESSING; RAT; REVIEW;

ANIMALS; DIPEPTIDYL PEPTIDASES; HUMANS; PROTEASE INHIBITORS; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; SUBSTRATE SPECIFICITY;

EID: 63849300555     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2735/3476     Document Type: Article

References (127)

1. C. A. Abbott, G. W. McCaughan and M. D. Gorrell: Two highly conserved glutamic acid residues in the predicted beta propeller domain of dipeptidyl peptidase IV are required for its enzyme activity. FEBS Lett, 458(3), 278-284(1999) (Pubitemid 29433819)
2. H. B. Rasmussen, S. Branner, F. C. Wiberg and N. Wagtmann: Crystal structure of human dipeptidyl peptidase IV/CD26 in a complex with substrate analog. Nat Struct Biol, 10, 19-25(2003) (Pubitemid 36034172)
3. K. Aertgeerts, S. Ye, M. G. Tennant, M. L. Kraus, J. Rogers, B. Sang, R. J. Skene, D. R. Webb and G. S. Prasad: Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation. Protein Sci, 13, 412-421(2004) (Pubitemid 38124962)
4. J. Kameoka, T. Tanaka, Y. Nojima, S. F. Schlossman and C. Morimoto: Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science, 261(5120), 466-9(1993) (Pubitemid 23276554)
5. W. T. Chen: DPPIV and seprase in cancer invasion and angiogenesis. Adv Exp Med Biol, 524, 197-203(2003)
6. W. T. Chen: Membrane proteases: roles in tissue remodeling and tumour invasion. Curr Opin Cell Biol, 4(5), 802-9(1992)
7. S. A. Miller, E. L. S. Onge and J. R. Taylor: DPP-IV inhibitors: A review of sitagliptin, vildagliptin, alogliptin, and saxagliptin. Formulary, 43(4), 122-+ (2008)
8. N. Mikhail: Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opin Investig Drugs, 17(6), 845-853(2008) (Pubitemid 351864322)
9. C. F. Deacon: Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. Curr Opin Investig Drugs, 9(4), 402-413(2008) (Pubitemid 351507666)
10. R. A. Defronzo, M. Hissa, M. B. Blauwet and R. S. Chen: Saxagliptin added to metformin improves glycemic control in patients with type 2 diabetes. Diabetes, 56, A74-A74 (2007)
11. L. S. Schlesselman: Sitagliptin - The first dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Formulary, 41(9), 434-+ (2006)
12. G. R. Lankas, B. Leiting, R. S. Roy, G. J. Eiermann, M. G. Beconi, T. Biftu, C. C. Chan, S. Edmondson, W. P. Feeney, H. B. He, D. E. Ippolito, D. Kim, K. A. Lyons, H. O. Ok, R. A. Patel, A. N. Petrov, K. A. Pryor, X. X. Qian, L. Reigle, A. Woods, J. K. Wu, D. Zaller, X. P. Zhang, L. Zhu, A. E. Weber and N. A. Thornberry: Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes - Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes, 54(10), 2988-2994(2005) (Pubitemid 41401097)
13. B. Ahren, M. Landin-Olsson, P. Jansson, M. Svensson, D. Holmes and A. Schweizer: Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes. J Clin Endocrinol Metab, 89, 2078-2084(2004) (Pubitemid 38619835)
14. P. E. Wiedeman and J. M. Trevillyan: Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes. Curr Opin Investig Drugs, 4(4), 412-20(2003) (Pubitemid 36681626)
15. J. A. Pospisilik, J. A. Ehses, T. Doty, C. H. McIntosh, H.-U. Demuth and R. A. Pederson: Dipeptidyl Peptidase IV Inhibition in Animal Models of Diabetes. In: Dipeptidyl Aminopeptidases in Health and Disease. Ed H. e. al. Kluwer Academic/Plenum Publishers, New York (2003)
16. D. J. Drucker: Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs, 12(1), 87-100(2003) (Pubitemid 36104645)
17. J. J. Holst, L. Hansen, C. Orskov, M. Wojdemann, A. Wetiergren and C. F. Deacon: GLP-1 (7-36amide) is transformed by dipeptidyl peptidase IV in the capillaries supplying the L-cells into GLP-1 (9-36amide), which antagonizes the gastrointestinal effects of GLP-1. Diabetes, 47, A30-A30 (1998)
18. J. J. Holst and C. F. Deacon: Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes, 47(11), 1663-70(1998) (Pubitemid 28476238)
19. S. Tanaka, T. Murakami, H. Horikawa, M. Sugiura, K. Kawashima and T. Sugita: Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int J Immunopharmacol, 19(1), 15-24(1997) (Pubitemid 27259665)
20. Y. N. Williams, H. Baba, S. Hayashi, H. Ikai, T. Sugita, S. Tanaka, N. Miyasaka and T. Kubota: Dipeptidyl peptidase IV on activated T cells as a target molecule for therapy of rheumatoid arthritis. Clin Exp Immunol, 131, 68-74(2003) (Pubitemid 36098824)
21. K. Augustyns, G. Bal, G. Thonus, A. Belyaev, X. M. Zhang, W. Bollaert, A. M. Lambeir, C. Durinx, F. Goossens and A. Haemers: The unique properties of dipeptidyl-peptidase IV (DPP IV/CD26) and the therapeutic potential of DPP IV inhibitors. Curr Med Chem, 6(4), 311-27(1999) (Pubitemid 29226115)
22. T. Shioda, H. Kato, Y. Ohnishi, K. Tashiro, M. Ikegawa, E. E. Nakayama, H. Hu, A. Kato, Y. Sakai, H. Liu, T. Honjo, A. Nomoto, A. Iwamoto, C. Morimoto and Y. Nagai: Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci U S A, 95(11), 6331-6(1998) (Pubitemid 28249012)
23. J. D. Jiang, S. Wilk, J. Li, H. Zhang and J. G. Bekesi: Inhibition of Human Immunodeficiency Virus type 1 infection in a T-cell line (Cem) by new dipeptidylpeptidase IV (CD26) inhibitors. Res Virol, 148(4), 255-266(1997) (Pubitemid 27345209)
24. D. Reinhold, S. Wrenger, U. Bank, F. Bühling, T. Hoffmann, K. Neubert, M. Kraft, R. Frank and S. Ansorge: CD26 mediates the action of HIV-1 Tat protein on DNA synthesis and cytokine production in U937 Cells. Immunobiol, 195(1), 119-128(1996) (Pubitemid 26054131)
25. C. Callebaut, B. Krust, E. Jacotot and A. G. Hovanessian: T cell activation antigen, CD26, as a cofactor for entry of HIV in CD4+ cells. Science, 262(5142), 2045-50(1993) (Pubitemid 24041886)
26. W. J. Rettig, P. Garin-Chesa, H. R. Beresford, H. F. Oettgen, M. R. Melamed and L. J. Old: Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc Natl Acad Sci U S A, 85(9), 3110-3114(1988)
27. A. Sedo, E. Krepela and E. Kasafirek: Dipeptidyl peptidase IV, prolyl endopeptidase and cathepsin B activities in primary human lung tumors and lung parenchyma. J Cancer Res Clin Oncol, 117(3), 249-53(1991)
28. U. V. Wesley, A. P. Albino, S. Tiwari and A. N. Houghton: A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. (see comment). J Exp Med, 190(3), 311-22(1999) (Pubitemid 29374829)
29. C. L. Pethiyagoda, D. R. Welch and T. P. Fleming: Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells. Clin Exp Metastasis, 18(5), 391-400(2000) (Pubitemid 32588619)
30. E. Schön, S. Jahn, S. T. Kiessig, H. U. Demuth, K. Neubert, A. Barth, R. Von-Bähr and S. Ansorge: The role of dipeptidyl peptidase IV in human T lymphocyte activation. Inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthesis in vitro. Eur J Immunol, 17(12), 1821-6(1987) (Pubitemid 18052052)
31. E. Schön and S. Ansorge: Dipeptidyl peptidase IV in the immune system. Cytofluorometric evidence for induction of the enzyme on activated T lymphocytes. Biol Chem Hoppe Seyler, 371(8), 699-705(1990) (Pubitemid 20277178)
32. E. Schön, I. Born, H. U. Demuth, J. Faust, K. Neubert, T. Steinmetzer, A. Barth and S. Ansorge: Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes. Biol Chem Hoppe Seyler, 372(5), 305-11(1991)
33. N. H. Dang and C. Morimoto: CD26: an expanding role in immune regulation and cancer. Histol Histopathol, 17(4), 1213-26(2002)
34. U. Aytac, F. X. Claret, L. Ho, K. Sato, K. Ohnuma, G. B. Mills, F. Cabanillas, C. Morimoto and N. H. Dang: Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicininduced cell cycle arrest at the G (2)/M checkpoint. Cancer Res, 61(19), 7204-10(2001) (Pubitemid 32946516)
35. F. J. Salgado, E. Vela, M. Martin, R. Franco, M. Nogueira and O. J. Cordero: Mechanisms of CD26/dipeptidyl peptidase IV cytokine-dependent regulation on human activated lymphocytes. Cytokine, 12(7), 1136-41(2000) (Pubitemid 30479501)
36. B. Bauvois, M. Djavaheri-Mergny, D. Rouillard, J. Dumont and J. Wietzerbin: Regulation of CD26/DPPIV gene expression by interferons and retinoic acid in tumor B cells. Oncogene, 19(2), 265-72(2000) (Pubitemid 30077223)
37. C. Nguyen, J. Blanco, J. P. Mazaleyrat, B. Krust, C. Callebaut, E. Jacotot, A. G. Hovanessian and M. Wakselman: Specific and irreversible cyclopeptide inhibitors of dipeptidyl peptidase IV activity of the T-cell activation antigen CD26. J Med Chem, 41(12), 2100-10(1998) (Pubitemid 28308627)
38. F. Buhling, U. Junker, D. Reinhold, K. Neubert, L. Jager and S. Ansorge: Functional role of CD26 on human B lymphocytes. Immunol Lett, 45(1-2), 47-51(1995)
39. D. Reinhold, U. Bank, F. Bühling, U. Lendeckel, A. J. Ulmer, H. D. Flad and S. Ansorge: Transforming growth factor-beta 1(TGF-beta 1) inhibits DNA synthesis of PWM-stimulated PBMC via suppression of IL-2 and IL-6 production. Cytokine, 6(4), 382-8(1994) (Pubitemid 24263883)
40. F. Buhling, D. Kunz, D. Reinhold, A. J. Ulmer, M. Ernst, H. D. Flad and S. Ansorge: Expression and functional role of dipeptidyl peptidase IV (CD26) on human natural killer cells. Nat Immun, 13(5), 270-9(1994) (Pubitemid 24326646)
41. D. Reinhold, U. Bank, F. Buhling, K. Neubert, T. Mattern, A. J. Ulmer, H. D. Flad and S. Ansorge: Dipeptidyl peptidase IV (CD26) on human lymphocytes. Synthetic inhibitors of and antibodies against dipeptidyl peptidase IV suppress the proliferation of pokeweed mitogen-stimulated peripheral blood mononuclear cells, and IL-2 and IL-6 production. Immunobiol, 188(4-5), 403-14(1993) (Pubitemid 23264757)
42. A. M. Lambeir, Durinx C., Scharpe S. and De Meester I.: Dipeptidyl-Peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPIV. Crit Rev Clin Lab Sci, 40(3), 209-294(2003) (Pubitemid 36775376)
43. M. D. Gorrell and D. Yu: Diverse functions in a conserved structure: The dipeptidyl peptidase IV gene family. In: Trends in Protein Research. Ed R. J. W. Nova Science Publishers Inc., (2005)
44. M. J. Scanlan, B. K. Raj, B. Calvo, P. Garin-Chesa, M. P. Sanz-Moncasi, J. H. Healey, L. J. Old and W. J. Rettig: Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci U S A, 91(12), 5657-61(1994) (Pubitemid 24174387)
45. M. T. Levy, G. W. McCaughan, C. A. Abbott, J. E. Park, A. M. Cunningham, E. Muller, W. J. Rettig and M. D. Gorrell: Fibroblast activation protein: A cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology, 29(6), 1768-1778(1999) (Pubitemid 29247051)
46. C. Y. Edosada, C. Quan, T. Tran, V. Pham, C. Wiesmann, W. Fairbrother and B. B. Wolf: Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly (2)-Pro (1)-cleaving specificity. FEBS Lett, 580(6), 1581-1586(2006) (Pubitemid 43290354)
47. W. T. Chen: Proteases associated with invadopodia, and their role in degradation of extracellular matrix. Enzyme Protein, 49(1-3), 59-71(1996)
48. M. L. Pineiro-Sanchez, L. A. Goldstein, J. Dodt, L. Howard, Y. Yeh, H. Tran, W. S. Argraves and W. T. Chen: Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease. J Biol Chem, 272(12), 7595-601(1997) (Pubitemid 27137306)
49. G. Ghersi, H. Dong, L. A. Goldstein, Y. Yeh, L. Hakkinen, H. S. Larjava and W. T. Chen: Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex. J Biol Chem, 277(32), 29231-41(2002)
50. G. Ghersi, H. Dong, L. A. Goldstein, Y. Yeh, L. Hakkinen, H. S. Larjava and W. T. Chen: Seprase-dPPIV association and prolyl peptidase and gelatinase activities of the protease complex. Adv Exp Med Biol, 524, 87-94(2003) (Pubitemid 36570814)
51. V. J. Christiansen, K. W. Jackson, K. N. Lee and P. A. McKee: Effect of fibroblast activation protein and alpha (2)-antiplasmin cleaving enzyme on collagen types I, III, and IV. Arch Biochem Biophys, 457(2), 177-186(2007) (Pubitemid 46048698)
52. S. Aggarwal, W. N. Brennen, T. P. Kole, E. Schneider, O. Topaloglu, M. Yates, R. J. Cotter and S. R. Denmeade: Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. Biochem, 47(3), 1076-1086(2008)
53. P. Busek, R. Malik and A. Sedo: Dipeptidyl peptidase IV activity and/or structural homologues (DASH) and their substrates in cancer. Int J Biochem Cell Biol, 36, 408-421(2004) (Pubitemid 37542440)
54. K. Wada, N. Yokotani, C. Hunter, K. Doi, R. J. Wenthold and S. Shimasaki: Differential Expression of 2 Distinct Forms of Messenger-Rna Encoding Members of a Dipeptidyl Aminopeptidase Family. Proc Natl Acad Sci U S A, 89(1), 197-201(1992)
55. T. Chen, K. Ajami, G. W. McCaughan, W. P. Gai, M. D. Gorrell and C. A. Abbott: Molecular characterization of a novel dipeptidyl peptidase like 2-short form (DPL2-s) that is highly expressed in the brain and lacks dipeptidyl peptidase activity. Biochim Biophys Acta - Prot Proteom, 1764(1), 33-43(2006) (Pubitemid 43362829)
56. C. A. Abbott and M. D. Gorrell: The family of CD26/DPIV related ectopeptidases. In: Ectopeptidases: CD13/Aminopeptidase N and CD26/Dipeptidylpeptidase IV in Medicine and Biology. Ed J. Langner & S. Ansorge. Kluwer/Plenum, New York (2002)
57. R. B. Hough, A. Lengeling, V. Bedian, C. Lo and M. Bucan: Rump white inversion in the mouse disrupts dipeptidyl aminopeptidase-like protein 6 and causes dysregulation of Kit expression. Proc Natl Acad Sci U S A, 95, 13800-13805(1998)
58. M. S. Nadal, A. Ozaita, Y. Amarillo, E. Vega-Saenz de Miera, Y. L. Ma, W. J. Mo, E. M. Goldberg, Y. Misumi, Y. Ikehara, T. A. Neubert and B. Rudy: The CD26-related dipeptidyl aminopeptidase-like protein DPPX is a critical component of neuronal A-type K+ channels. Neuron, 37(3), 449-461(2003) (Pubitemid 36183366)
59. H. H. Jerng, Y. Qian and P. J. Pfaffinger: Modulation of Kv4.2 channel expression and gating by dipeptidyl peptidase 10(DPP10). Biophys J, 87(4), 2380-2396(2004) (Pubitemid 41071337)
60. S. Y. Qi, P. J. Riviere, J. Trojnar, J. L. Junien and K. O. Akinsanya: Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases. Biochem J, 373(Pt 1), 179-89(2003) (Pubitemid 36819513)
61. J. Schade, M. Stephan, A. Schmiedl, L. Wagner, A. J. Niestroj, H. U. Demuth, N. Frerker, C. Klemann, K. A. Raber, R. Pabst and S. von Horsten: Regulation of expression and function of dipeptidyl peptidase 4(DP4), DP8/9, and DP10 in allergic responses of the lung in rats. J Histochem Cytochem, 56(2), 147-155(2008) (Pubitemid 351170967)
62. M. Allen, A. Heinzmann, E. Noguchi, G. Abecasis, Brozholme, C. P. Ponting, S. Bhattaharyya, J. Tinsley, Y. Zhange, R. Holt, E. Y. Jones, N. Lench, A. Carey, H. Hones, N. J. Dickens, C. Dimon, R. Nicholls, C. Baker, L. Xue, E. Townsend, M. Kabesch, S. K. Wieland, D. Carr, E. Mutius and I. M. e. a. Adcock: Positional cloning of a novel gene influencing asthma from Chromosome 2q14. Nat Genet, 35(3), 258-263(2003) (Pubitemid 37363180)
63. D. A. Fox and H. R. E.: Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody. J Immunol, 133(3), 1250-1256(1984) (Pubitemid 14060073)
64. B. Fleischer: A novel pathway of human T cell activation via a 103kDa T cell activation antigen. J Immunol, 138(5), 1346-50(1987) (Pubitemid 17029424)
65. O. J. Cordero, F. J. Salgado, J. E. Vinuela and M. Nogueira: Interleukin-12 enhances CD26 expression and dipeptidyl peptidase IV function on human activated lymphocytes. Immunobiol, 197(5), 522-33(1997) (Pubitemid 27490000)
66. M. J. Scanlan, B. K. M. Raj, B. Calvo, P. Garinchesa, M. P. Sanzmoncasi, J. H. Healey, L. J. Old and W. J. Rettig: Molecular-Cloning of Fibroblast Activation Protein-Alpha, a Member of the Serine-Protease Family Selectively Expressed in Stromal Fibroblasts of Epithelial Cancers. Proc Natl Acad Sci U S A, 91(12), 5657-5661(1994) (Pubitemid 24174387)
67. J. E. Park, M. C. Lenter, R. N. Zimmermann, P. Garin-Chesa, L. J. Old and W. J. Rettig: Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem, 274(51), 36505-36512(1999)
68. M. A. Huber, N. Kraut, J. E. Park, R. D. Schubert, W. J. Rettig, R. U. Peter and P. Garin-Chesa: Fibroblast activation protein: Differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors. J Invest Dermatol, 120(2), 182-188(2003) (Pubitemid 36513065)
69. G. Ghersi, Q. Zhao, M. Salamone, Y. Yeh, S. Zucker and W. T. Chen: The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices. Cancer Res, 66(9), 4652-61(2006)
70. X. M. Wang, D. M. T. Yu, G. W. McCaughan and M. D. Gorrell: Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology, 42(4), 935-945(2005) (Pubitemid 41401132)
71. M. S. Nadal, Y. Amarillo, E. Vega-Saenz de Miera and B. Rudy: Differential characterization of three alternative spliced isoforms of DPPX. Brain Res, 1094, 1-12(2006) (Pubitemid 43927609)
72. K. Takimoto, Y. Hayashi, X. M. Ren and N. Yoshimura: Species and tissue differences in the expression of DPPY splicing variants. Biochem Biophys Res Commun, 348(3), 1094-1100(2006) (Pubitemid 44233527)
73. X. M. Ren, Y. Hayashi, N. Yoshimura and K. Takimoto: Transmembrane interaction mediates complex formation between peptidase homologues and Kv4 channels. Mol Cell Neurosci, 29(2), 320-332(2005) (Pubitemid 40725621)
74. C. A. Abbott, D. M. T. Yu, E. Woollatt, G. R. Sutherland, G. W. McCaughan and M. D. Gorrell: Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem, 267(20), 6140-6150(2000)
75. H. Zhu, Z. M. Zhou, L. Lu, M. Xu, H. Wang, J. M. Li and J. H. Sha: Expression of a novel dipeptidyl peptidase 8(DPP8) transcript variant, DPP8-v3, in human testis. Asian J Androl, 7(3), 245-255(2005) (Pubitemid 41288546)
76. K. Ajami, C. A. Abbott, G. W. McCaughan and M. D. Gorrell: Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim Biophys Acta (2004)
77. C. Olsen and N. Wagtmann: Identification and characterisation of human DPP9, a novel homologue of dipeptidyl peptidase IV. Gene, 299, 185-193(2002) (Pubitemid 35379840)
78. J. R. Bjelke, J. Christensen, P. F. Nielsen, S. Branner, A. B. Kanstrup, N. Wagtmann and H. B. Rasmussen: Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV. Biochem J, 396, 391-399(2006) (Pubitemid 43837255)
79. Y. Misumi, Y. Hayashi, F. Arakawa and Y. Ikehara: Molecular cloning and sequence analysis of human dipeptidyl peptidase IV, a serine proteinase on the cell surface. Biochim Biophys Acta, 1131(3), 333-6(1992)
80. C. Harland, T. Shah, A. D. Webster and T. J. Peters: Dipeptidyl peptidase IV-subcellular localization, activity and kinetics in lymphocytes from control subjects, immunodeficient patients and cord blood. Clin Exp Immunol, 74(2), 201-5(1988)
81. S. Iwaki-Egawa, Y. Watanabe, Y. Kikuya and Y. Fujimoto: Dipeptidyl peptidase IV from human serum: purification, characterization, and N-terminal amino acid sequence. J Biochem (Tokyo), 124(2), 428-33(1998) (Pubitemid 28419692)
82. H. Shibuya-Saruta, Y. Kasahara and Y. Hashimoto: Human serum dipeptidyl peptidase IV (DPPIV) and its unique properties. J Clin Lab Anal, 10(6), 435-40(1996) (Pubitemid 26398936)
83. K. N. Lee, K. W. Jackson, V. J. Christiansen, C. S. Lee, J. G. Chun and P. A. McKee: Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood, 107(4), 1397-1404(2006) (Pubitemid 43242374)
84. H. H. Jemg, A. D. Lauver and P. J. Pfaffinger: DPP10 splice variants are localized in distinct neuronal populations and act to differentially regulate the inactivation properties of KvA-based ion channels. Mol Cell Neurosci, 35(4), 604-624(2007) (Pubitemid 47176897)
85. V. Dubois, A. M. Lambeir, P. Van der Veken, K. Augustyns, J. Creemers, X. Chen, S. Scharpe and I. De Meester: Purification and characterisation of dipeptidyl peptidase 9 - like enzyme from bovine testes. Front Biosci, 13, 3558-3568(2008) (Pubitemid 351594704)
86. N. Bilodeau, A. Fiset, G. G. Poirier, S. Fortier, M. C. Gingras, J. N. Lavoie and R. L. Faure: Insulin-dependent phosphorylation of DPP IV in liver. Evidence for a role of compartmentalized c-Src. FEBS J, 273(5), 992-1003(2006)
87. C. S. Shu. H, Bi. Q, Mumb. M, Brekken D. L: Identification of Phosphoproteins and Their Phosphorylation Sites in the WEHI-231 B Lymphoma Cell Line. Mol Cell Proteom, 3(3), 279-86(2004) (Pubitemid 38714284)
88. K. Aertgeerts, I. Levin, L. H. Shi, G. P. Snell, A. Jennings, G. S. Prasad, Y. M. Zhang, M. L. Kraus, S. Salakian, V. Sridhar, R. Wijnands and M. G. Tennant: Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. J Biol Chem, 280(20), 19441-19444(2005) (Pubitemid 41379462)
89. P. Strop, A. J. Bankovich, K. Hansen, K. C. Garcia and A. T. Brunger: Structure of a human A-type potassium channel accelerating factor DPPX, a member of the dipeptidyl aminopeptidase family. Biophys J, 88(1), 456A-456A (2005)
90. M. R. Pitman, R. I. Menz and C. A. Abbott: Prediction of dipeptidyl peptidase (DP) 8 structure by homology modelling. In: Dipeptidyl Aminopeptidases: Basic Science and Clinical Applications. Springer, New York (2006)
91. M. G. Rummey C: Homology Modelling of Dipeptidyl Peptidases 8 and 9 with a Focus on Loop Predictions Near the Active Site. Prot Struct Funct Bioinf, 66, 160-171(2007)
92. M. D. Gorrell: Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci, 108(4), 277-92(2005) (Pubitemid 40516992)
93. H. J. Lee, Y. S. Chen, C. Y. Chou, C. H. Chien, C. H. Lin, G. G. Chang and X. Chen: Investigation of the dimer interface and substrate specificity of prolyl dipeptidase DPP8. J Biol Chem, 281(50), 38653-62(2006) (Pubitemid 46041990)
94. P. M. Ajami K, Wilson CH, Park J, Menz RI, Starr AE, Cox JH, Abbott CA, Overall CM, Gorrell MD: Stromal cell-derived factors 1alpha and 1beta, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8. FEBS Lett, 582(5), 819-25(2008)
95. I. L. Lu, S. J. Lee, H. Tsu, S. Y. Wu, K. H. Kao, C. H. Chien, Y. Y. Chang, Y. S. Chen, J. H. Cheng, C. N. Chang, T. W. Chen, S. P. Chang, X. Chen and W. T. Jiaang: Glutamic acid analogues as potent dipeptidyl peptidase IV and 8 inhibitors. Bioorg Med Chem Lett, 15(13), 3271-3275(2005) (Pubitemid 40799072)
96. P. Van der Veken, A. Soroka, I. Brandt, Y. S. Chen, M. B. Maes, A. M. Lambeir, X. Chen, A. Haemers, S. Scharpe, K. Augustyns and I. De Meester: Irreversible inhibition of dipeptidyl peptidase 8 by dipeptide-derived diaryl phosphonates. J Med Chem, 50(23), 5568-5570(2007) (Pubitemid 350106012)
97. M. B. Maes, V. Dubois, I. Brandt, A. M. Lambeir, P. Van der Veken, K. Augustyns, J. D. Cheng, X. Chen, S. Scharpe and I. De Meester: Dipeptidyl peptidase 8/9-like activity in human leukocytes. J Leukoc Biol, 81(5), 1252-1257(2007) (Pubitemid 46702044)
98. C. Shaffer: Incretin mimetics vie for slice of type 2 diabetes market. Nat Biotechnol, 25(3), 263-263(2007)
99. I. Idris and R. Donnelly: Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diab Obes Metab, 9(2), 153-165(2007) (Pubitemid 46206559)
100. B. Ahren: Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep, 3(5), 365-72(2003) (Pubitemid 38906794)
101. J. J. Holst: Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diab Metab Res Rev, 18(6), 430-41(2002) (Pubitemid 36041598)
102. R. Mentlein: Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides. Regul Pept, 85(1), 9-24(1999) (Pubitemid 29505281)
103. R. Mentlein, B. Gallwitz and W. E. Schmidt: Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem, 214(3), 829-35(1993) (Pubitemid 23188160)
104. A. Barnett: DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract, 60(11), 1454-1470(2006) (Pubitemid 44560347)
105. C. K. Chakraborti: The potential role of vildagliptin in the management and prevention of type 2 diabetes mellitus. Indian J Pharm, 40(1), 10-14(2008)
106. J. Rosenstock, S. Sankoh and J. F. List: Glucoselowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diab Obes Metab, 10(5), 376-386(2008) (Pubitemid 351524285)
107. J. List, J. Rosenstock, S. Sankoh and R. Chen: Saxagliptin improves glycaemic control as monotherapy in type 2 diabetes. Diabetologia, 50, S367-S367 (2007)
108. T. Ishii, K. Ohnuma, A. Murakami, N. Takasawa, S. Kobayashi, N. H. Dang, S. F. Schlossman and C. Morimoto: CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. PNAS, 98(21), 12138-43(2001) (Pubitemid 32959840)
109. D. M. T. Yu, X. M. Wang, G. W. McCaughan and M. D. Gorrell: Extra-enzymatic functions of the dipeptidyl peptidase IV-related proteins DP8 and DP9 in cell adhesion, migration and apoptosis. FEBS J, 273, 2447-2460(2006) (Pubitemid 43736658)
110. C. Cunningham, D. Richards, R. Salgia, R. Leonard, R. Raju, B. Berman, S. Anthony, Z. J. Yang, L. Gregoire, E. Haltom and M. J. Uprichard: A phase 2 study of talabostat/docetaxel in advanced NSCLC. Clin Cancer Res, 11(24), 9056S-9057S (2005)
111. T. F. Gajewski, D. H. Lawson, B. G. Redman, C. Cunningham, S. Agarwala, M. S. Ernstoff, E. J. Haltom, L. Gregoire and M. G. J. Uprichard: A phase 2 study of talabostat in patients with stage IV melanoma. J Immunother, 28(6), 626-626(2005)
112. C. Cunningham, D. Richards, R. Salgia, R. Leonard, R. Raju, J. Arseneau, S. Packer, L. Gregoire, L. Haltom and M. J. Uprichard: Phase 2 trial of talabostat and docetaxel in patients with stage IIIb/IV NSCLC. J Clin Oncol, 23(16), 650S-650S (2005)
113. M. J. Uprichard, S. J. O'Day, A. C. Pavlick, D. A. Richards, G. Frenette, J. Stephenson, S. Anthony, P. A. Pacciucci, V. Vrhovac and C. Cunningham: Phase 2 study of talabostat and cisplatin in stage IV melanoma. J Clin Oncol, 23(16), 725S-725S (2005)
114. B. G. Redman, M. S. Ernstoff, T. F. Gajewski, C. Cunningham, D. H. Lawson, L. Gregoire, E. Haltom and M. J. Uprichard: Phase 2 trial of talabostat in stage IV melanoma. J Clin Oncol, 23(16), 727S-727S (2005)
115. A. Al-Katib, D. D. Hurd, R. Raju, J. Stephenson, F. Giles, E. Haltom and M. J. Uprichard: Phase 1 study of talabostat and rituximab in patients with indolent Non-Hodgkin's Lymphoma with primary resistance to or progression following rituximab. Blood, 104(11), 394A-394A (2004)
116. J. A. McIntyre and J. Castaner: Talabostat. Oncolytic, hematopoietic agent, dipeptidyl-peptidase IV (CD26) inhibitor, fibroblast activation protein inhibitor. Drug Future, 29(9), 882-886(2004) (Pubitemid 39531756)
117. M. P. Jesson M, Miller G, Adams S, Aubin J, Jones B.: Mechanism of Action of Talabostat: A Dipeptidyl Peptidase Targeted Anti-Tumor Agent. In: American Association of Cancer Research (AACR) Annual Meeting. Point Therapeutics, Boston, MA (2007)
118. M. Saleh: Caspase-1 builds a new barrier to infection. Cell, 126(6), 1028-1030(2006) (Pubitemid 44380305)
119. X. Wang, M. Narayanan, J. M. Bruey, D. Rigamonti, E. Cattaneo, J. C. Reed and R. M. Friedlander: Protective role of Cop in Rip2/caspase-1/caspase-4- mediated HeLa cell death. Biochim Biophys Acta-Mol Basis Dis, 1762(8), 742-754(2006) (Pubitemid 44293374)
120. C. Stehlik, S. H. Lee, A. Dorfleutner, A. Stassinopoulos, J. Sagara and J. C. Reed: Apoptosisassociated speck-like protein containing a caspase recruitment domain is a regulator of procaspase-1 activation. J Immunol, 171(11), 6154-6163(2003) (Pubitemid 37467238)
121. J. D. Correia, Y. Miranda, N. Leonard, J. Hsu and R. J. Ulevitch: Regulation of Nod1-mediated signaling pathways. Cell Death Differ, 14(4), 830-839(2007) (Pubitemid 46444520)
122. E. W. Humke, S. K. Shriver, M. A. Starovasnik, W. J. Fairbrother and V. M. Dixit: ICEBERG: A novel inhibitor of interleukin-1 beta generation. Cell, 103(1), 99-111(2000)
123. M. Razmara, S. M. Srinivasula, L. Wang, J. L. Poyet, B. J. Geddes, P. S. DiStefano, J. Bertin and E. S. Alnemri: CARD-8 protein, a new CARD family member that regulates caspase-1 activation and apoptosis. J Biol Chem, 277(16), 13952-13958(2002) (Pubitemid 34968002)
124. M. Arndt, U. Lendeckel, A. Spiess, J. Faust, K. Neubert, D. Reinhold and S. Ansorge: Dipeptidyl peptidase IV (DP IV/CD26) mRNA expression in PWM-stimulated T-cells is suppressed by specific DP IV inhibition, an effect mediated by TGF-beta (1). Biochem Biophys Res Commun, 274(2), 410-414(2000) (Pubitemid 30614332)
125. D. Reinhold, B. Hemmer, B. Gran, I. Born, J. Faust, K. Neubert, H. F. McFarland, R. Martin and S. Ansorge: Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4+ T cell clones. J Neuroimmunol, 87(1-2), 203-9(1998) (Pubitemid 28319863)
126. W. L. DeLano: The PyMOL Molecular Graphics System. In: DeLano Scientific, Palo Alto, CA, USA (2002)
127. W. Jiaang, Y. Chen, T. Hsu, S. Wu, C. Chien, C. Chang, S. Chang, L. SJ. and X. Chen: Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8 Bioorg Med Chem Lett, 15(3), 687-691(2005) (Pubitemid 40143148)